Missing Script

Get updates

Evidence Explorer / MS-N204 / Supportive physical care / Appraised November 1, 2026

A small pilot randomized trial suggested lower skin-color changes with a film-forming silicone gel, while a 2026 MASCC practice statement judged StrataXRT the best-supported barrier-forming agent in its class. The practice statement is expert guidance informed by evidence; it is not a new efficacy trial.

Evidence at a glance

  • Trial population: 56 people receiving breast radiotherapy.
  • Comparator: StrataXRT vs X-derm moisturizer.
  • Trial finding: lower post-treatment erythema and melanin indices in post hoc/repeated-measures analyses.
  • 2026 guidance: MASCC recommends considering barrier-forming agents for patients at considerable risk of high-grade dermatitis; it says StrataXRT has the most robust support within the class.
  • Evidence label: promising but limited direct trial evidence, strengthened by current consensus guidance.

What was studied

The pilot trial reported group-by-time interactions for erythema (P=.008) and melanin index (P=.015). These are objective skin measurements, but the abstract does not establish a prespecified clinically meaningful difference in dermatitis grade.

The MASCC statement was published October 5, 2026 after a literature search through April 23, 2026 and structured expert discussion. It addresses patient selection, skin preparation, product choice, application and monitoring. The authors declared no competing interests.

What this evidence cannot establish

A 56-person pilot with post hoc analyses is not enough on its own to establish a universal standard. Physiological skin indices are not identical to patient-important outcomes such as pain, moist desquamation, infection or treatment interruption.

The guidance explicitly notes that robust data are still needed for routine use across anatomical sites. Its recommendation is strongest for people at considerable risk, particularly irregular contours such as head and neck.

Practical safety context

Film-forming gel should be used according to the radiation service’s instructions; too-thick application, incomplete drying or use on infected/open tissue may create problems.

Report rash, severe itching, blistering, drainage, fever or rapidly worsening pain. Do not add other topical products under a barrier without checking compatibility.

Questions for the care team

  • Am I at sufficiently high risk for a barrier-forming agent to be reasonable?
  • Why is this product preferred over a dressing or topical steroid in my setting?
  • What application thickness, drying time and stopping rules does the team use?

Sources

Source note: The pilot full text, PubMed records and October 2026 MASCC statement abstract were checked. The guidance and pilot are different source types and are not counted as two efficacy trials. Funding and conflict information is reported only where it was available in the checked source. No correction, retraction or expression of concern was identified in the PubMed-linked record on November 1, 2026.

This record is educational. It is not a personal treatment recommendation and does not replace advice from the oncology or radiation-care team. Symptom or toxicity outcomes do not demonstrate tumor response, recurrence prevention or longer survival.